NCT00537901

Brief Summary

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2007

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2007

Completed
Same day until next milestone

Study Start

First participant enrolled

October 1, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 2, 2007

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2013

Completed
Last Updated

December 17, 2015

Status Verified

December 1, 2015

Enrollment Period

6 years

First QC Date

October 1, 2007

Last Update Submit

December 16, 2015

Conditions

Colonic NeoplasmsRectal Neoplasms

Keywords

Colon and Rectum Cancer

Outcome Measures

Primary Outcomes (1)

  • Effectiveness

    overall

Secondary Outcomes (1)

  • Quality of life

    overall

Interventions

First-Line Bevacizumab and ChemotherapyRADIATION

Chemotherapy

BevacizumabDRUG

Chemotherapy

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with metastatic cancer of colon or rectum

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Colonic NeoplasmsRectal Neoplasms

Interventions

Drug TherapyBevacizumab

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

TherapeuticsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Shouki Bazarbashi, MD

    KFSH & RC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 1, 2007

First Posted

October 2, 2007

Study Start

October 1, 2007

Primary Completion

October 1, 2013

Study Completion

October 1, 2013

Last Updated

December 17, 2015

Record last verified: 2015-12